Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:06:09.993Z.
Calculation as of: 2026-10-06T14:06:09.993Z.
Quote observation: 2026-10-06T14:05:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 273f4a35489c6dcba82bfbf6813c8f243fa8fa5e32baf23fc33ea9a1b57f5f97
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | $177.22M | N/A | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $178.56M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.31M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $173.89M | N/A | N/A | N/A | N/A |
| MediWound Ltd. (MDWD)vs › | $172.65M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $182.88M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $165.46M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $191.97M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $160.80M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $159.74M | N/A | 2.79 | 2.79 | 2.79 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute